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Purpose: Anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis is being recognized 
with increasing frequency among children. Given the paucity of evidence to guide the 
critical care management of these complex patients, we provide a comprehensive review 
of the literature with pooled analysis of published case reports and case series.
Methods: We performed a comprehensive literature search using PubMed, Scopus, 
EMBASE, and Web of Science for relevant published studies. The literature search was 
conducted using the terms NMDA, anti-NMDA, Anti-N-methyl-d-aspartate, pediatric 
encephalitis, and anti-NMDAR and included articles published between 2005 and May 
1, 2016.
Results: Forty-eight references met inclusion criteria accounting for 373 cases. For 
first-line treatments, 335 (89.8%) received high-dose corticosteroids, 296 received intra-
venous immunoglobulin (79.3%), and 116 (31%) received therapeutic plasma exchange. 
In these, 187 children (50.1%) had a full recovery with only minor deficits, 174 patients 
(46.7%) had partial recovery with major deficits, and 12 children died. In addition, 14 
patients were reported to require mechanical ventilation.
Conclusion: Anti-NMDA encephalitis is a formidable disease with great variation in clin-
ical presentation and response to treatment. With early recognition of this second most 
common cause of pediatric encephalitis, a multidisciplinary approach by physicians may 
provide earlier access to first- and second-line therapies. Future studies are needed to 
examine the efficacy of these current therapeutic strategies on long-term morbidity.
Keywords: N-methyl-d-aspartate receptor, N-methyl-d-aspartate, encephalitis, autoimmune, critical care, 
pediatrics, paraneoplastic
Abbreviations: CT, Cat scan; CNS, central nervous system; CPR, cardiopulmonary resuscitation; CSF, cerebrospinal fluid; 
EEG, electroencephalogram; IVIG, intravenous immunoglobulin; MRI, magnetic resonance imaging; NMDAR, N-methyl-d-
aspartate receptor; PICU, pediatric intensive care unit.
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iNTRODUCTiON
Pediatric critical care physicians are increasingly called upon 
to diagnose, manage, and treat children with anti-N-methyl-
d-aspartate receptor (anti-NMDAR) encephalitis. Anti-NMDAR 
encephalitis was originally described in 2005 in four women with 
ovarian teratomas, presenting with seizures, acute psychiatric 
disturbances, cognitive deficits, decreased sensorium, autonomic 
instability, and hypoventilation (1). Dalmau et al. in 2007 diag-
nosed these women and eight others after demonstrating specific 
autoantibodies to the NMDAR; namely, a neuronal cell surface 
protein that was shown to be the NR1 subunit of the receptor (2).
Since the first reported cases and discovery of anti-NMDAR 
encephalitis, this disease has surpassed all single viral etiologies 
and has been recognized as the second most common entity after 
the mixed disturbance encephalomyelitis, acute demyelinating 
encephalitis (2, 3). The estimated mortality for anti-NMDAR 
encephalitis in one series of 100 adults with a median age of 
23  years was 4% (4). Although over 600 adult and pediatric 
cases have been reported in the literature with 2 case series of 
15 patients and 77 patients among critically ill adults, further 
critical care-focused considerations have been lacking (5–12). 
Nonetheless, some authors have suggested that earlier treatment 
in children may result in better outcomes (13–15). We reviewed 
the literature to evaluate the use of corticosteroids and intravenous 
immunoglobulin (IVIG) as a first-line therapy for patients with 
anti-NMDAR encephalitis. Next, we provide a pooled analysis of 
reviewed data and critical care considerations based on literature 
review for critically ill children with anti-NMDAR encephalitis.
MATeRiALS AND MeTHODS
We conducted a search of PubMed, Scopus, EMBASE, and Web 
of Science to identify relevant published studies and abstracts 
and then conducted a systematic, narrative review of potentially 
relevant sources. The literature search was conducted using the 
terms NMDA, anti-NMDA, anti-NMDAR, pediatric encephali-
tis, and anti-NMDAR and included articles published between 
January 1, 2005, and May 1, 2016. Furthermore, the search was 
limited to “humans,” children, and abstracts or reports published 
in English, and screening was performed by the first author 
(Kenneth E. Remy). Our search criteria are included in the 
supplemental information. Inclusion criteria were any clinical 
study or report in which subjects (1) demonstrated anti-NMDA 
receptor encephalitis by positive serum and/or cerebrospinal 
fluid (CSF) anti-NMDAR and (2) were younger than 19  years 
(intended age, 0–18  years). Exclusion criteria included (1) the 
absence of a laboratory data to support the diagnosis, i.e., no 
evidence of serum and/or CSF NMDAR antibodies; (2) adults 
older than 18 years; or (3) publications not in English. Since the 
majority of this information was individual case reports, this 
information was combined and tabulated to document current 
practice. The variables collected included age; sex; presence of 
positive CSF or blood anti-NMDA receptor titers; use of first-line 
therapies including high-dose corticosteroids, IVIG, or plasma 
exchange; use of second-line therapies such as rituximab or cyclo-
phosphamide; and need for mechanical ventilation. Outcome 
measures were modified from previous studies and classified as 
complete recovery with only mild deficit, partial recovery with 
significant deficit, and death (8, 16). One of the authors (Kenneth 
E. Remy) retrospectively assigned all patients to one of these out-
come groups. As this review was performed on published reports 
and lacked patient identifying data, the University of Maryland 
Institutional Review Board waived the need for approval.
ReSULTS
The search identified 862 potentially relevant studies, and 201 
were selected for data extraction. From these, 48 references met 
inclusion criteria, including 27 individual case reports and 21 
case series (Figure 1) (4, 10–12, 14, 15, 17–57). Two prospective 
cohort studies were found (45, 53). One large retrospective cohort 
series accounted for 211 patients (14). The presence of both clini-
cal diversity and methodological diversity precluded combining 
the study reports in a meta-analysis. Whenever possible, authors 
were electronically mailed for missing data.
A total of 382 patients were included; however, incomplete data 
were included in the case reports for 9 patients. Thus, 373 patients 
with a mean age of 9.98 years (range, 3 months–18 years) were 
included in our pooled data analysis presented in Table 1. Larger 
case series that included only means and range of ages precluded 
calculation of SD of mean age. The pooled analysis included 254 
females (68.1%) and 119 (31.9%) males (9 reports did not include 
sex). Subjects represented nine different countries. Sixty-five of 
66 patients with evidence of teratoma (17.6%) were females, as 
described in the original case reports (1). Anti-NMDA titers were 
positive in the CSF and serum of 327 (87.6%) and 276 (74%) 
patients, respectively.
For first-line treatments (as reported as first agent given or 
delineated in report), 335 (89.8%) received high-dose corticoster-
oids, 296 received IVIG (79.3%), and 116 (31%) received thera-
peutic plasma exchange. Five patients received electroconvulsive 
therapy (ECT) (34, 46, 50–52), and 14 children required mechani-
cal ventilation (11, 12, 22, 28, 37, 38, 42, 44, 52, 53, 55, 56). There 
were five reports that explicitly defined the use of intensive care 
or pediatric intensive care unit although some reports alluded 
to need for “advanced” therapies (30, 34, 38, 54, 55). In reported 
outcomes, 187 children (50.1%) had a full recovery with only 
minor deficits, while 174 patients (46.7%) had partial recovery 
with major deficits at 1-year follow-up. Twelve children (3.2%) 
died subsequent to their disease.
To best define the use of first- and second-line therapies, we 
next examined the reports that provided delineation between 
initiations of specific therapies. In 15 reports of 20 patients that 
defined a time period before first agent and initiation of second 
agent, 13 patients received high corticosteroids administered 
on mean day 8.71 (SD ± 3.2) and 7 patients received IVIG on 
mean day 7.57 (SD ± 7.7) (19, 21, 25, 27–30, 32, 36, 37, 41, 42, 49, 
50, 58). The mean time course from reported first agent to second 
in these 15 reports was 11.4 days (SD ± 15.6). Second-line therapies 
included rituximab in 87 patients (23.3%) and cyclophosphamide 
62 patients (16.6%). In this cohort of 15 reports (n = 19 patients), 
clinical duration of symptoms began 31.3 ±  20.1 days prior to 
admission (range, 1–90  days). Time to complete resolution 
FigURe 1 | Flow diagram of the published articles evaluated for inclusion in pooled analysis.
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of symptoms was 115.6 ± 86 days (range, 21–279 days; n = 15 
patients), and four patients did not have complete resolution.
DiSCUSSiON
We pooled data from all relevant case reports, case series, and 
available retrospective cohort studies to better characterize the 
disease epidemiology, treatment modalities, and clinical out-
comes of children with anti-NMDAR encephalitis.
epidemiology
Anti-N-methyl-d-aspartate receptor encephalitis affects both 
males and females, with a higher incidence among females (75% 
cases) (8, 32, 52, 59–62). Although it was originally described as a 
paraneoplastic disease with 58% patients showing evidence of an 
underlying tumor (most commonly ovarian teratoma), published 
literature reports only 31 and 9% of children younger than 18 years 
and younger than 14 years, respectively, had evidence of tumor 
(8, 16). As non-Caucasians have a higher incidence of ovarian 
teratomas, they also have higher incidence of anti-NMDAR 
encephalitis (32, 59). This association has been described in chil-
dren as young as 3 months of age; however, most of the reported 
cases are adolescents (21, 61, 63, 64). In our pooled analysis, we 
have identified similar findings to those reported previously, with 
almost 70% of cases being female, an average age of 10 years, and 
18% patients having a teratoma.
Despite these data, the diagnosis of anti-NMDAR encephalitis 
is still uncommon with many cases designated as idiopathic and 
possible or probable. Only 79 patients had identifiable diagnoses 
in the California Encephalitis Project of 761 cases, with 32 chil-
dren having anti-NMDAR encephalitis (4.2%) and 30 children 
with enteroviral encephalitis (3.9%). Within this cohort, DuBray 
et  al. described that 11% of children with encephalitis at her 
single center (compared to the entire centers in the project) 
occurred secondary to Mycoplasma infection, with a slightly 
lower incidence of 3.6% resulting from anti-NMDAR antibodies 
(65). Of interest, one-half of the cases with idiopathic psychiatric 
symptoms had antibodies against NMDAR (3, 22). This raises 
TAbLe 1 | Pooled analysis.
Total patients 373 children
Sex 254F (68.1%) 119 M (31.9%)
Mean age 9.98 years (range, 3–18 years)
Teratoma or malignancy present 66 (17.6%)
CSF positive for anti-NMDAR 327 (87.6%)
Serum positive for anti-NMDAR 276 (74%)
First-line treatments
High-dose corticosteroids 335 (89.8%)
Intravenous immunoglobulin 296 (79.3%)
Plasma exchange 116 (31%)
Second-line treatments
Rituximab 87 (23.3%)
Cyclophosphamide 62 (16.6%)
Third-line treatments
Electroconvulsive therapy 5 (1.3%)
Mechanical ventilation 14 (3.8%)
Outcomes
Complete recovery with minor deficits 187 (50.1%)
Partial recovery with major deficits 174 (46.7%)
Death 12 (3.2%)
TAbLe 2 | Proposed therapies for anti-NMDAR encephalitis.
First-line therapies (if tumor is 
present, begin after removal)
Second-line therapies (if disease is 
refractory after 10 days)
IVIG 0.4 g/kg for 5 days and 
methylprednisolone 30 mg/kg daily for 
5 days or plasma exchange daily for 
six cycles
Rituximab 375 mg/m2 weekly for 
4 weeks and cyclophosphamide 
750 mg/m2 monthly (duration is based 
on clinical improvement)
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the question whether children with postinfectious encephalitis 
(i.e., HSV and Mycoplasma) and without tumor develop anti-
NMDAR antibodies as parts of a larger, nonspecific immune 
response to these pathogens. The inciting infection may trigger 
antibodies directed against NMDAR, and thus, unusual presen-
tations of viral encephalitis should be screened for concomitant 
autoimmune encephalitis (17, 42). Awareness of this disease 
and the availability of diagnostic molecular tests may improve 
our ability to diagnose the underlying etiologies of pediatric 
encephalitides.
Clinical Course
Some authors have described anti-NMDAR encephalitis as hav-
ing three clinical stages; a prodromal stage, an early (psychotic 
and/or seizure phase), and a late (hyperkinetic) phase (62, 66). 
Most interestingly, serum and CSF antibody titers seem to 
correlate with the disease course: a decline in titers coincides 
with improvement in symptoms (16). In the prodromal stage, 
symptoms include fever, nausea, vomiting, or upper respiratory 
tract infection-like symptoms (4, 22, 31, 67). This prodrome may 
last up to 2 weeks in 70% of patients (2, 31). During the early 
stage, patients may develop psychiatric symptoms such as fear, 
delusions, mania, and/or paranoia—manifesting in children as 
behavioral disturbances and tantrums rather than an underly-
ing pathologic process. Children are more likely than adults to 
present with seizures, dystonia, or status epilepticus (11). Within 
3–4 weeks, a more fulminant stage develops. Rapid disintegration 
of speech and language, hyperactivity, mutism, and irritability are 
often seen. Progression to decreased responsiveness, catatonia, 
autonomic instability, cardiac arrhythmias, hypoventilation, and 
uncoordinated respiration can lead to rapid deterioration and 
need for critical care interventions. Autonomic dysregulation 
and hypoventilation are less common in children than adults, 
while speech dysfunction appears more frequently (22, 68). 
During treatment, recovery has been described as reversal of 
symptoms in the reverse order of presentation (16).
Diagnostic evaluation
Once clinical suspicion is raised, all patients presenting with 
encephalitis should be evaluated for anti-NMDAR antibod-
ies and receive imaging studies to exclude the presence of a 
teratoma (62, 69). Definitive diagnosis is made by CSF evidence 
of anti-NMDAR antibodies. CSF studies usually demonstrate 
an elevated white blood cell count, lymphocytic pleocytosis 
in 87% of children, and oligoclonal bands in 60% of patients 
(16, 31, 69). In our analysis, most patients had positive serum 
and/or CSF antibodies to NMDAR. However, one must interpret 
our findings with caution as reporting bias may falsely elevate 
positive results. While examining for anti-NMDAR encepha-
litis, one should also consider other encephalitides including 
AMPA-R, metabotropic glutamate receptor, voltage-gated 
potassium channels (LGI1, CASPR2, or contactin-2), anti-Hu, 
anti-CV2, anti-CRM, anti-P5, anti-MA proteins, voltage-gated 
calcium channel defects, GABAB-R, glycine-R, and GABAA-R 
defects (53, 70, 71).
Clinical Management
When there is high clinical suspicion for the disease, rapid treat-
ment should occur in a stepwise fashion as confirmatory testing 
is not performed at some centers and may take days to weeks 
(62, 66). The known pathophysiology and current (low-grade) 
evidence suggests that starting therapy earlier may lead to better 
outcomes. With appropriate treatment, substantial improvement 
or complete recovery can occur in up to 75% of patients (4, 14). 
However, relapses may occur in approximately 25% of children 
even after resolution (8). Surgical removal of a teratoma or other 
tumor is necessary but should not delay initiation of definitive 
therapy. In our small cohort of reports that defined clinical 
symptom time course of presentation and resolution after treat-
ment, there was great variation among different aged patients and 
response to therapies. This makes generalizations of presentation 
and treatment findings difficult to assess. However, from current 
evidence, first-line therapies have included plasma exchange, 
IVIG, or high-dose corticosteroids. Based on all available infor-
mation, it seems that IVIG therapy with 0.4 g/kg daily for 5 days 
or 1 g/kg on day 1 followed by 0.5 g/kg/day for 2 additional days 
and methylprednisolone 1 g (adults) or 30 mg/kg (children up 
to 40 kg) daily for 3 days or daily plasma exchange for six cycles 
would likely have favorable clinical effects (Table 2). In refractory 
cases or critically ill patients, second-line immunomodulation 
with rituximab or cyclophosphamide may be attempted (2, 4, 8, 
27, 31). In adults and children, combined second-line therapies of 
rituximab 375 mg/m2 weekly for 4 weeks and cyclophosphamide 
750 mg/m2 monthly have been proposed (27, 51). After therapy 
TAbLe 3 | Intensive care symptom-guided therapies.
Symptoms First-line therapy Second-line 
therapy
Refractory 
therapy
Agitation Trihexyphenidyl 
(0.02–0.06 mg/kg 
or 1 mg 1–2 times 
daily) and low-dose 
opioids (fentanyl 1 
μg/kg/h infusion or 
bolus)
Dexmedetomidine 
infusion (0.2 μg–1.5 
μg/kg/min)
Propofol infusion 
(10–30 μg/kg/min)
Catatonia 
autonomic 
dysfunction 
bradycardia
Glycopyrrolate 
(0.004–0.01 mg/
kg q4–8 h prn: 
maximum, 
0.1–0.2 mg/dose, 
0.8 mg/day)
Theophylline (begin 
oral 300 mg/day 
divided q4–6 h up 
to a maximum dose 
600 mg/24 h)
Electroconvulsive 
therapy
Hypoventilation Tracheostomy 
(if ventilated for 
>4 weeks)
Additional 
considerations
Gastric-tube 
placement
Early physical 
therapy
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is completed, some authors recommend yearly screening with 
pelvic magnetic resonance imaging to assess for ovarian tumors 
(8, 32, 69). Details of critical care management for individual 
patients were unavailable for us to define treatment benefit with 
individual treatment approaches. Future prospective studies 
should evaluate the need and indications for ICU admission, 
duration of ICU care, complications associated with the disease 
and/or treatments, and evaluation of all-cause mortality among 
patients with this disease.
Critical Care Considerations
Children with significant neurological symptoms should be 
initially managed in an ICU as autonomic dysfunction, airway 
protection, hypoventilation, cardiac arrhythmia, or hyperkinetic 
crisis may occur. Pediatric critical care requires an interdiscipli-
nary team including neurologists, psychiatrists, cardiologists, 
nutritionists, physical therapists, social workers, physiatrists, 
pastoral care, and child life experts. Symptom-guided therapies 
are listed in Table 3.
There are two main variations of instability that require 
critical care management: a neurologic type with catatonic or 
hyperkinetic crises and one that manifests with autonomic and 
hemodynamic instability (10, 27, 50). Although 84% of children 
have hyperkinetic movements, the literature is lacking in effec-
tive therapies (8). Valproic acid, gabapentin, and lithium have 
been used for mood dysregulation (25, 28, 31, 72). Clonidine, 
trazodone, and benzodiazepines target sleep cycle dysregulation, 
and phenobarbital, trihexyphenidyl (Artane™), and opioids are 
used for extreme agitation (10, 25, 28, 30, 38, 50). For catatonia, 
benzodiazepines or rarely ECTs have been reported (8, 16, 51, 
73, 74). Routine management of agitation may include low-dose 
opioids, other sedatives, anxiolytics, or anti-psychotic drugs. For 
refractory agitation, methotrimeprazine or dexmedetomidine 
infusion may be beneficial for both intubated and non-intubated 
patients. For continued refractory symptoms, mechanical 
ventilation and low-dose propofol or ketamine infusions may 
be beneficial, although used with extreme caution. Careful atten-
tion and laboratory surveillance are needed to avoid propofol 
infusion syndrome, especially for children younger than 5 years 
and those receiving propofol for longer than 24 hours (75–78). 
Barbiturates and dexmedetomidine should be used at the low-
est possible dosing to avoid bradycardia. Non-pharmacological 
therapies (noise reduction, adjusting room ambiance) should be 
employed to avoid agitation. Finally, muscle relaxants should be 
avoided to avoid ICU myopathies, especially with concomitant 
corticosteroid therapy (79).
The autonomic and hemodynamic instability can be difficult 
to manage. Resting tachycardia is widely reported in multiple case 
studies of pediatric patients (4, 8, 11). However, severe bradycar-
dia and asystole events may be exacerbated by vagal stimulation 
including endotracheal tube suctioning or bowel movements 
(36, 80). Foley catheter use, bowel regimens to prevent constipa-
tion, and careful suctioning of the endotracheal tube are essential 
to minimize parasympathetic stimulation. Bradycardia events 
were also associated with seizures in this patient population 
and continuous electroencephalogram should be considered to 
capture these events (81).
Chronic use of medications such as glycopyrrolate or theo-
phylline may be considered for preventing severe bradycardia; 
these medications have been successful in other disease processes 
to prevent symptomatic bradycardia (82). If severe bradycardia is 
frequent and unresponsive to medical therapies, an implantable 
pacemaker may be considered (83). Brain imaging to diagnose 
hydrocephalus may be indicated with new onset of bradycardia 
events in some patients (69).
Autonomic dysfunction also manifests as impaired tempera-
ture or blood pressure regulation. While patients are maintained 
on immunosuppressant therapies, infectious etiologies for hypo-
thermia/hyperthermia must be considered. We have observed 
that movement disorders are often exacerbated during the febrile 
state; aggressive temperature control should be implemented 
with antipyretics, environmental cooling, and cooling blankets 
as indicated.
Hypoventilation in ICU patients with anti-NMDAR encepha-
litis may make it difficult to wean from mechanical ventilation. 
Ventilator weaning in these patients is further complicated by 
delirium, agitation, and movement disorders that may require 
heavy sedation. Placement of a tracheostomy and gastrostomy 
tube in the third week after diagnosis may improve patient safety 
and allow for less sedation and earlier rehabilitation.
Once medically feasible, it is paramount to begin a compre-
hensive rehabilitation program including physical, occupational, 
speech, and dysphagia therapy to improve long-term outcomes 
(24, 84). Functional decline in motor skills and cognition is 
common among patients with anti-NMDAR encephalitis and 
physical therapists with physiatrists should be engaged early in 
their management.
The available heterogeneous data impose methodological 
limitations for pooled analysis. Thus, one weakness of this 
review is the lack of statistical analysis for successful treatment 
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or prognostic indicators. Our recommendations are limited to 
available low-grade evidence. However, this study provides a first 
step toward conducting randomized controlled trials to evaluate 
the efficacy of potential therapies.
CONCLUSiON
Anti-N-methyl-d-aspartate receptor encephalitis is a commonly 
encountered adult and pediatric critical care diagnosis. Careful 
understanding of the clinical features of the disease, diagnosis, 
and treatment options may improve the care of these complex 
patients. Early rehabilitation and careful consideration for 
tracheostomy and gastrostomy placement may further improve 
functional outcomes. Future studies investigating both phar-
macologic approaches and non-pharmacologic interventions 
of autonomic dysfunction, movement disorders, and cardiac 
arrhythmias will be important in improving patient care and 
outcomes.
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